



The **complexity of current HTA processes** across Member States require significant administrative and financial resources and time from developers and can cause access delays.

The EU HTA procedure must lead to sufficient harmonisation of existing methodologies and wide uptake of joint EU HTA reports to avoid the risk of additional clinical assessments being demanded at Member State level. **The aim should be to prevent the duplication of work, reduce burdens and increase the predictability for all involved stakeholders.**

EUCOPE's PRIORITIES FOR THE EU HTA REGULATION:

1

Joint Scientific Consultation must be offered to all developers

2

A flexible methodology that accounts for the specificities of Orphan Medicinal Products (OMPs) and Advanced Therapy Medicinal Products (ATMPs)

3

Procedures for resolving multiple and competing comparator requests

4

Ensure the broad involvement of relevant stakeholders

5

A transparent and balanced selection of experts